A Study To Evaluate The Safety And Pharmacokinetic Profile Of A P38 Inhibitor (PH-797804) In Subjects With Rheumatoid Arthritis Who Are Also Taking Methotrexate



Status:Completed
Conditions:Arthritis, Rheumatoid Arthritis
Therapuetic Areas:Rheumatology
Healthy:No
Age Range:18 - Any
Updated:11/10/2018
Start Date:March 2008
End Date:October 2008

Use our guide to learn which trials are right for you!

A 4-Week, Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study To Evaluate The Safety And Pharmacokinetic Profile Of 1 And 5 Mg Ph-797804 Administered Once Daily In Subjects With Rheumatoid Arthritis Who Are Taking Oral Methotrexate

The hypothesis of this study is that the p38 inhibitor (PH-797804) will be safe and well
tolerated in subjects with rheumatoid arthritis who are taking methotrexate and will not
effect the blood levels of methotrexate.


Inclusion Criteria:

- Adult with RA for at least 6 months

- Stable weekly dosage of oral methotrexate 12.5- 25 mg/week

Exclusion Criteria:

- Severe, progressive and/or uncontrolled other disease

- Chronic or recent serious infection; current infection

- Concomitant use of RA therapy other than methotrexate with some exceptions
We found this trial at
7
sites
Bingham Farms, Michigan 48025
?
mi
from
Bingham Farms, MI
Click here to add this to my saved trials
Colorado Springs, Colorado 80918
?
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
Duncansville, Pennsylvania 16635
?
mi
from
Duncansville, PA
Click here to add this to my saved trials
Frederick, Maryland 21702
?
mi
from
Frederick, MD
Click here to add this to my saved trials
Kalamazoo, Michigan 49048
?
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
Miami, Florida 33155
?
mi
from
Miami, FL
Click here to add this to my saved trials
Phoenix, Arizona 85016
?
mi
from
Phoenix, AZ
Click here to add this to my saved trials